In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Emerging concepts on heart rate

  • Heart rate and cardiovascular function, presented by J L Lopez-Sendon (Madrid, ES) - Slides
  • Heart rate and coronary artery disease, presented by U C Hoppe (Salzburg, AT) - Slides
  • Pharmacological modulation of heart rate, presented by W J Remme (Rhoon, NL) - Slides
  • Implications of recent studies, presented by JS Borer (New York, US) - Slides
Cardiovascular Pharmacology and Pharmacotherapy

Heart rate and cardiovascular function

The session started with an excellent update about heart rate and cardiovascular function presented by Dr. Lopez Sendon from Spain. He emphasized the consistent evidence in the relationship between heart rate and outcomes in cardiovascular trials, in particular those studies in heart failure patients, where highest is heart rate worst is the prognosis. He also showed different mechanisms used by drugs reducing heart rate, most of them linked to oxygen consumption.

Heart rate and coronary artery disease

Dr. Uta Hoppe, from Cologne, analysed in a very detailed way, all others pathways used and produced by heart rate reduction in coronary patients. They include vessels elasticity, plaque stability, among others, but she also agreed on the crucial role of oxygen consumption.

Pharmacological modulation of heart rate

The following presenter was Dr. Willem Remme from the Netherlands who reviewed all groups of drugs modulating heart rate and demonstrated that beta blockers and ivabradine are the most effective. The last one is being confirmed as a “pure heart rate reduction” compound.

Implications of recent studies

Finally, Jeffrey Borer from USA made a very interesting comment about the implication of recent trials using ivabradine. He presented some new results of subgroups from the Shift study, demonstrating clear benefits in cardiac haemodynamic and quality of life.

In summary it was a provocative session updating the growing importance of high heart rate as a maker of poor prognosis in cardiovascular diseases, mainly ischaemic disease and heart failure.




Emerging concepts on heart rate

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.